UBS Maintains Neutral on Pfizer, Lowers Price Target to $27
Portfolio Pulse from Benzinga Newsdesk
UBS analyst Colin Bristow has maintained a Neutral rating on Pfizer (NYSE:PFE) and reduced the price target from $34 to $27.
December 14, 2023 | 4:47 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
UBS analyst Colin Bristow maintains a Neutral rating on Pfizer and lowers the price target from $34 to $27.
The reduction in price target by UBS suggests a more conservative valuation of Pfizer, which could lead to a negative short term reaction in the stock price as investors adjust their expectations.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100